Sjoerd H. van der Burg

Research interests

Publications

• Therapeutic cancer vaccines

  Nature reviews. Cancer · 2021 · 10.1038/s41568-021-00346-0

• Monalizumab: inhibiting the novel immune checkpoint NKG2A

  Journal for ImmunoTherapy of Cancer · 2019 · 10.1186/s40425-019-0761-3

• Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer

  JAMA Oncology · 2018 · https://doi.org/10.1001/jamaoncol.2018.4051

• NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines

  Cell · 2018 · 10.1016/j.cell.2018.10.028

• Actively personalized vaccination trial for newly diagnosed glioblastoma

  Nature · 2018 · https://doi.org/10.1038/s41586-018-0810-y

• Neoantigen landscape dynamics during human melanoma–T cell interactions

  Nature · 2016 · 10.1038/nature18945

• Vaccines for established cancer: overcoming the challenges posed by immune evasion

  Nature reviews. Cancer · 2016 · 10.1038/nrc.2016.16

• Therapeutic cancer vaccines

  Journal of Clinical Investigation · 2015 · 10.1172/jci80009

• Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry

  Cancer Immunology Immunotherapy · 2015 · https://doi.org/10.1007/s00262-015-1729-x

• CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses

  Biomaterials · 2014 · 10.1016/j.biomaterials.2014.10.053

• High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

  Nature Medicine · 2014 · 10.1038/nm.3773

• Classification of current anticancer immunotherapies

  Oncotarget · 2014 · https://doi.org/10.18632/oncotarget.2998

• Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment

  Cancer Research · 2013 · 10.1158/0008-5472.can-12-3542

• A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence

  Nature · 2013 · https://doi.org/10.1038/nature12154

• Identification and manipulation of tumor associated macrophages in human cancers

  Journal of Translational Medicine · 2011 · 10.1186/1479-5876-9-216

• M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells

  The Journal of Immunology · 2011 · 10.4049/jimmunol.1100889

• Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

  New England Journal of Medicine · 2009 · 10.1056/nejmoa0810097

• Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

  Clinical Cancer Research · 2008 · 10.1158/1078-0432.ccr-07-1880

• Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

  Clinical Cancer Research · 2008 · 10.1158/1078-0432.ccr-07-1881

• Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

  Nature reviews. Cancer · 2008 · 10.1038/nrc2373

• High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

  Cancer Research · 2007 · 10.1158/0008-5472.can-06-3388

• CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity

  The Journal of Immunology · 2007 · 10.4049/jimmunol.179.8.5033

• Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

  Cancer Research · 2004 · 10.1158/0008-5472.can-04-0831

• Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides

  The Journal of Immunology · 2002 · 10.4049/jimmunol.169.1.350

• Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability

  The Journal of Immunology · 1996 · 10.4049/jimmunol.156.9.3308

• In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

  European Journal of Immunology · 1993 · 10.1002/eji.1830230905

Current projects

No projects listed.